Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to compare two ophthalmic solutions in patients with open-angle glaucoma or ocular hypertension.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alcon Research
• Treatments: Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Travoprost

Criteria

Inclusion Criteria:

• 18 years or older.

• Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as specified in protocol.

• Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.

• Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least one continuous month prior to Visit 1.

• Willing and able to discontinue use of any topical ocular medicine other than the study medication for the duration of the study, including artificial tears.

• Best corrected visual acuity of -0.6 logMAR or better in each eye.

• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Any medical condition (systemic or ophthalmic) that may preclude safe administration of the test article.

• Use of contact lenses within 30 days of Visit 1.

• Use of contact lenses during the study.

• Participation in an investigational drug or device study within 30 days of entering this study.

• Other protocol-defined exclusion criteria may apply.